22. Acute Right Ventricular Failure

Quick Recap

Cardiovascular System, new protocol. Companion to Obstructive Shock, Vasopressor & Inotrope Selection & Titration, and Massive & Submassive PE (all Cardiovascular System) — addresses RV failure as a distinct physiological entity deserving its own framework, given how fundamentally different RV physiology is from the LV-centric approach most hemodynamic teaching defaults to.

1. Definition

Acute RV failure results from an inability to compensate for excessive preload, elevated afterload, or reduced myocardial contractility — producing RV dilation and hypokinesis, which compromises LV filling (via ventricular interdependence) and reduces cardiac output. Seen with increasing frequency in the ICU, and when severe, can independently cause hemodynamic instability and insufficient oxygen delivery.

2. Why RV Physiology Genuinely Differs From LV Physiology

The pulmonary circulation operates under fundamentally lower pressure than the systemic circulation, and the thin, compliant-walled RV tolerates large volume increases well but adapts poorly to acute afterload increases — this asymmetry (volume-tolerant, pressure-intolerant) is the central organizing principle for RV failure management, and directly explains why afterload reduction (lowering PA pressure) is a central priority in a way it typically isn't for LV failure management.

A distinct, genuinely important coronary perfusion pattern: unlike the LV (perfused predominantly during diastole), the RV is normally perfused during BOTH systole and diastole given the pressure gradient involved — but as RV systolic pressure rises toward systemic levels (e.g., in severe pulmonary hypertension), systolic right coronary artery blood flow falls, approaching zero as RV pressure approaches systemic levels. This creates a genuinely vicious cycle: elevated RV afterload directly compromises the RV's own coronary perfusion, worsening contractility, which further impairs the RV's ability to generate the pressure needed to maintain adequate perfusion elsewhere — maintaining adequate systemic (and therefore coronary perfusion) pressure is not just a general hemodynamic goal but a specific RV-self-preservation mechanism in this population.

3. Diagnosis — Echocardiographic Assessment

Bedside echocardiography (apical four-chamber view) is the practical, rapid assessment tool: RV:LV chamber size ratio >1, or RV end-diastolic diameter >30mm at mid-level, indicates RV dilation and possible elevated right-sided pressures. Loss of IVC inspiratory collapse indicates increased RA filling pressure. Parasternal short axis view: interventricular septal flattening ("D-sign") reflects elevated RV pressure relative to LV.

A specific, useful acute-vs-chronic distinguisher: RV free wall thickness above 5mm suggests CHRONIC RV overload rather than a purely acute process — useful when trying to determine whether a dilated RV reflects a new acute insult (PE, RV MI) versus a chronically remodeled RV now decompensating acutely.

RV-pulmonary artery (PA) coupling is the more sophisticated modern echocardiographic concept — normalizing RV contractility indices (TAPSE, RV free wall longitudinal strain) for the afterload (systolic PA pressure) the RV is working against, via ratios like TAPSE/PASP. This reflects the RV's actual efficiency of adaptation to its afterload, not just raw contractility in isolation, and both TAPSE/PASP and strain/PASP ratios have shown prognostic value in pulmonary hypertension and heart failure populations.

4. Vasoactive Drug Selection — A Genuinely Nuanced, Sometimes-Conflicting Picture

The theoretically ideal vasopressor for RV failure would increase systemic arterial pressure and RV contractility WITHOUT raising pulmonary vascular resistance — no single available agent perfectly satisfies all three criteria, making this a genuine tradeoff-weighing exercise rather than a single "correct" choice.

• Norepinephrine: primarily α1-mediated vasoconstriction with limited β1 (contractility) effect; animal models suggest the β1 component improves RV/PA coupling, but a human sepsis-with-RV-failure study found norepinephrine improved RV myocardial oxygen delivery (via increased SVR/coronary perfusion) while ALSO increasing pulmonary vascular resistance, with NO change in RV ejection fraction — a genuinely mixed result worth holding onto rather than assuming norepinephrine straightforwardly helps RV function just because it supports coronary perfusion pressure
• Vasopressin: an "attractive" option specifically because it is a potent systemic vasoconstrictor with comparatively little effect on the pulmonary vasculature — avoiding the PVR-raising downside that catecholamine vasopressors carry
• Dobutamine: at low doses (5-10mcg/kg/min), improves PA/RV coupling and myocardial contractility with favorable pulmonary vascular effects in left heart failure populations — a reasonable inotrope choice, though higher doses risk tachyarrhythmia and increased myocardial oxygen demand
• Levosimendan and PDE-III inhibitors (milrinone): combine RV inotropy with pulmonary vasodilation — potentially preferentially favorable specifically for pulmonary hypertension caused by LEFT heart disease given this dual mechanism; however, these agents should be used cautiously in acute RV myocardial infarction specifically, since they increase myocardial oxygen demand and arrhythmogenicity in a context where coronary supply is already the primary problem — a genuine, population-specific caution, not a universal preference
• Oral pulmonary arterial hypertension agents are generally ineffective for acute RV shock given their slow onset and dependence on oral absorption — not a rescue option in the acute setting regardless of their chronic disease-modifying value

Practical synthesis: there is no single "best" vasopressor/inotrope combination for RV failure — selection should be individualized to the specific cause (RV MI vs. pulmonary-hypertension-driven vs. septic RV dysfunction) and should weigh the genuine, sometimes-conflicting effects on contractility, systemic pressure, and pulmonary vascular resistance simultaneously, rather than defaulting to a single agent reflexively.

5. Mechanical Support Options

Beyond pharmacologic support, device options include RV-specific percutaneous devices (e.g., Impella RP), VA-ECMO, and a genuinely newer concept: pumpless lung-assist devices connecting the pulmonary artery to the left atrium via a low-resistance membrane oxygenator — pulmonary blood flow through this low-resistance circuit directly unloads the RV while simultaneously enhancing LV filling, a mechanistically elegant approach to the RV's core problem (excess afterload) rather than simply adding external pump support. Cross-reference Post-Cardiotomy Mechanical Circulatory Support (Cardiac Surgery Critical Care) for RV-specific device selection in that population.

6. Practical Synthesis

1. Identify and reverse the specific cause (PE, RV MI, ARDS-related pulmonary hypertension, sepsis) as the first priority — RV failure management is fundamentally cause-directed, not generic
2. Maintain adequate systemic/coronary perfusion pressure as an RV-self-preservation strategy, not merely a general hemodynamic target, given the RV's unique systolic-and-diastolic coronary perfusion dependence
3. Avoid excessive fluid administration — the volume-tolerant-but-afterload-intolerant RV physiology means overfilling can worsen ventricular interdependence and paradoxically reduce LV filling/output, the opposite of the intended effect
4. Select vasoactive agents based on the specific clinical context, not a single reflexive default — vasopressin or careful norepinephrine titration for systemic pressure support; dobutamine or levosimendan/milrinone for contractility, with genuine caution around the latter two in acute RV MI specifically
5. Use RV-PA coupling concepts (TAPSE/PASP) where available for a more sophisticated assessment than raw contractility measures alone
6. Escalate to mechanical support (RV-specific device, VA-ECMO, or newer pumpless lung-assist approaches) when pharmacologic measures are inadequate

7. Consultation Matrix

8. Documentation & Medicolegal Checklist

• Suspected/confirmed cause of RV failure documented
• Echocardiographic findings (RV:LV ratio, free wall thickness, TAPSE/PASP if obtained) documented
• Rationale for specific vasoactive agent selection, given the genuinely context-dependent nature of this choice, documented

9. Key Guidelines

• Konstam MA, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018 — foundational AHA statement
• Right ventricular failure. N Engl J Med. 2023;388(12):1111-1125 — contemporary review

10. Landmark Evidence

11. Controversies

• No single vasopressor/inotrope combination has been established as "best" for RV failure — this protocol treats agent selection as genuinely individualized to cause and context, consistent with the current literature's own acknowledgment of this gap (explicitly titled "Gaps and Knowledge in the Contemporary Management of Acute RV Failure" in one recent review).
• Norepinephrine's net effect on RV function in humans is genuinely more ambiguous than animal-model data alone would suggest — the one human sepsis study cited here found a mixed result (better O2 delivery, worse PVR, no RVEF change), and this protocol treats this as real uncertainty rather than resolving it in favor of the more optimistic animal-model mechanism.
• Newer device concepts (pumpless PA-to-LA lung-assist devices) remain early-stage and not yet broadly validated — mechanistically elegant, but this protocol does not present this as an established, guideline-endorsed therapy.

12. References

1. Konstam MA, Kiernan MS, Bernstein D, et al. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e578-e622.
2. Right ventricular failure. N Engl J Med. 2023;388(12):1111-1125.
3. Management of Acute Right Ventricular Failure in the Intensive Care Unit. Ann Am Thorac Soc.
4. Managing Acute Right Ventricular Failure. EMRA.
5. Epidemiology and management of right ventricular-predominant heart failure and shock in the cardiac intensive care unit. Eur Heart J Acute Cardiovasc Care. 2022;11(7):584.
6. Gaps and Knowledge in the Contemporary Management of Acute Right Ventricular Failure. Circ Heart Fail. 2024.
7. Is there a 'best' vasopressor and inotrope combination for shock with RV failure? CHEST Physician. 2025.
8. Prognostic Value of Echocardiographic RV-PA Coupling in Advanced Heart Failure. Echocardiography. 2025;42:e70348.

See also: Obstructive Shock (Cardiovascular System) for the broader shock differential RV failure fits within; Massive & Submassive PE (Cardiovascular System) for the most common acute precipitant; Vasopressor & Inotrope Selection & Titration (Cardiovascular System) for the general hemodynamic support framework this protocol adds RV-specific nuance to; Post-Cardiotomy Mechanical Circulatory Support (Cardiac Surgery Critical Care) for RV-specific device selection in the post-surgical population.